Wealth Enhancement Advisory Services LLC Has $15.89 Million Holdings in Becton, Dickinson and Company $BDX

Wealth Enhancement Advisory Services LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 90,225 shares of the medical instruments supplier’s stock after purchasing an additional 8,115 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Becton, Dickinson and Company were worth $15,894,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. GQG Partners LLC bought a new position in Becton, Dickinson and Company during the 1st quarter worth $689,833,000. Vanguard Group Inc. increased its position in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after purchasing an additional 1,259,750 shares during the period. Nuveen LLC acquired a new stake in Becton, Dickinson and Company in the first quarter valued at about $211,097,000. GAMMA Investing LLC boosted its stake in Becton, Dickinson and Company by 29,654.0% in the first quarter. GAMMA Investing LLC now owns 744,445 shares of the medical instruments supplier’s stock valued at $170,523,000 after buying an additional 741,943 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier’s stock valued at $1,567,654,000 after buying an additional 667,957 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.6%

NYSE BDX opened at $187.27 on Monday. The company has a market cap of $53.68 billion, a price-to-earnings ratio of 33.68, a P/E/G ratio of 1.51 and a beta of 0.27. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The business has a 50 day moving average price of $187.65 and a 200-day moving average price of $189.91. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter in the prior year, the company posted $3.50 earnings per share. Becton, Dickinson and Company’s revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is 74.82%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,965 shares of company stock valued at $551,536 in the last quarter. 0.36% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on BDX shares. Barclays cut their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 3rd. Piper Sandler reissued a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Argus lifted their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Finally, Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Four analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and an average price target of $213.30.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.